CLINICAL TRIAL: PHASE I DOSE ESCALATION STUDY OF AUTOLOGOUS TUMOR LYSATE-PULSED
临床试验:自体肿瘤裂解物脉冲的 I 期剂量递增研究
基本信息
- 批准号:8167071
- 负责人:
- 金额:$ 2.37万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-12-01 至 2010-11-30
- 项目状态:已结题
- 来源:
- 关键词:AutologousAutologous Dendritic CellsBrain NeoplasmsClinical TrialsCoculture TechniquesComputer Retrieval of Information on Scientific Projects DatabaseDendritic CellsDoseDose-LimitingFundingGrantHarvestImmune responseInstitutionMalignant GliomaMaximum Tolerated DoseMonitorOperative Surgical ProceduresPatientsPhasePhysiologic pulseResearchResearch PersonnelResourcesSchemeSourceTissuesToxic effectUnited States National Institutes of Healthintradermal injectionperipheral bloodtumortumor progression
项目摘要
This subproject is one of many research subprojects utilizing the
resources provided by a Center grant funded by NIH/NCRR. The subproject and
investigator (PI) may have received primary funding from another NIH source,
and thus could be represented in other CRISP entries. The institution listed is
for the Center, which is not necessarily the institution for the investigator.
SPECIFIC AIMS:
The primary objective of the study is:
To determine if Dose Limiting Toxicity (DLT) is reached in the dose escalation scheme described, using intradermal injections of autologous dendritic cells harvested from peripheral blood precursors and pulsed (co-cultured) with tumor lysate taken from surgical tissues in patients with malignant gliomas. If DLT is reached, then Maximum tolerated Dose (MTD) will be defined.
Secondary objectives of this study are:
To monitor survival, tumor progression and cellular immune responses in brain tumor patients injected with tumor lysate-pulsed dendritic cells.
这个子项目是众多研究子项目之一
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Linda M Liau其他文献
Linda M Liau的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Linda M Liau', 18)}}的其他基金
Project 1: Active immunotherapy combined with checkpoint modulation for glioblastoma
项目1:主动免疫疗法联合检查点调节治疗胶质母细胞瘤
- 批准号:
10225550 - 财政年份:2017
- 资助金额:
$ 2.37万 - 项目类别:
Novel mouse models using MADR-GESTALT technology to accelerate glioma research
使用 MADR-GESTALT 技术加速神经胶质瘤研究的新型小鼠模型
- 批准号:
10709379 - 财政年份:2017
- 资助金额:
$ 2.37万 - 项目类别:
Incorporation of Novel MADR-GESTALT Technology into UCLA SPORE in Brain Cancer
将新型 MADR-GESTALT 技术纳入 UCLA SPORE 治疗脑癌
- 批准号:
10271986 - 财政年份:2017
- 资助金额:
$ 2.37万 - 项目类别:
Project 1: Active immunotherapy combined with checkpoint modulation for glioblastoma
项目1:主动免疫疗法联合检查点调节治疗胶质母细胞瘤
- 批准号:
9983047 - 财政年份:2017
- 资助金额:
$ 2.37万 - 项目类别:
Incorporation of Novel MADR-GESTALT Technology into UCLA SPORE in Brain Cancer
将新型 MADR-GESTALT 技术纳入 UCLA SPORE 治疗脑癌
- 批准号:
10709378 - 财政年份:2017
- 资助金额:
$ 2.37万 - 项目类别:
相似海外基金
Evaluation of a therapeutic vaccination strategy with motif neoepitope peptide-pulsed autologous dendritic cells for non-small cell lung cancer patients harboring a charged HLA-B binding pocket.
使用基序新表位肽脉冲的自体树突状细胞对携带带电 HLA-B 结合袋的非小细胞肺癌患者的治疗性疫苗接种策略进行评估。
- 批准号:
10721983 - 财政年份:2023
- 资助金额:
$ 2.37万 - 项目类别:
ADMIN OF AUTOLOGOUS DENDRITIC CELLS ACTIVATED BY GM-CSF & IL-4 AS TUMOR VACCINE
GM-CSF 激活的自体树突状细胞的管理
- 批准号:
7603704 - 财政年份:2007
- 资助金额:
$ 2.37万 - 项目类别:
ADMIN OF AUTOLOGOUS DENDRITIC CELLS ACTIVATED BY GM-CSF & IL-4 AS TUMOR VACCINE
GM-CSF 激活的自体树突状细胞的管理
- 批准号:
7376503 - 财政年份:2006
- 资助金额:
$ 2.37万 - 项目类别:
ADMIN OF AUTOLOGOUS DENDRITIC CELLS ACTIVATED BY GM-CSF & IL-4 AS TUMOR VACCINE
GM-CSF 激活的自体树突状细胞的管理
- 批准号:
7199818 - 财政年份:2005
- 资助金额:
$ 2.37万 - 项目类别:
MATURED, RENAL TUMOR RNA-TRANSFECTED AUTOLOGOUS DENDRITIC CELLS
成熟的肾肿瘤 RNA 转染自体树突状细胞
- 批准号:
7198472 - 财政年份:2005
- 资助金额:
$ 2.37万 - 项目类别:
PH II EVAL OF IMMUNIZATION TUMOR CELLS SEZARY SYND AUTOLOGOUS DENDRITIC CELLS
免疫肿瘤细胞 SEZARY SYND 自体树突状细胞的 PH II 评估
- 批准号:
7201137 - 财政年份:2005
- 资助金额:
$ 2.37万 - 项目类别:
EMERG TRMENT IMMUNIZ TUMOR CELLS W/MYCOSIS FUNGOIDS AUTOLOGOUS DENDRITIC CELLS
带有真菌病蕈样菌的紧急免疫肿瘤细胞自体树突细胞
- 批准号:
7201139 - 财政年份:2005
- 资助金额:
$ 2.37万 - 项目类别:
Admin of Autologous Dendritic Cells Activated by GM-CSF & IL-4 as Tumor Vaccine
GM-CSF 激活的自体树突状细胞的管理
- 批准号:
7039780 - 财政年份:2004
- 资助金额:
$ 2.37万 - 项目类别:
Phase 1 clinical trial of autologous dendritic cells to induce antigen-specific tolerance
自体树突状细胞诱导抗原特异性耐受的一期临床试验
- 批准号:
nhmrc : 301244 - 财政年份:2004
- 资助金额:
$ 2.37万 - 项目类别:
NHMRC Development Grants
ANTIPSEUDOMONAS VACCINE OF AUTOLOGOUS DENDRITIC CELLS EXPRESSING CD40 LIGAND
表达 CD40 配体的自体树突细胞的抗假单胞菌疫苗
- 批准号:
6668357 - 财政年份:2002
- 资助金额:
$ 2.37万 - 项目类别: